Sanofi-Aventis Menactra Market Is $3.5 Bil. Over 10 Years, CDC Says
Executive Summary
The potential market for Sanofi-Aventis' meningococcal conjugate vaccine Menactra is $3.5 bil. over 10 years, a Centers for Disease Control & Prevention analysis indicates
You may also be interested in...
Sanofi-Aventis Menactra Approved; Launch Awaits ACIP Recommendations
Sanofi-Aventis' launch of its meningococcal conjugate vaccine Menactra will await formal recommendations for use by the Centers for Disease Control & Prevention's Advisory Committee on Immunization Practices next month
Sanofi-Aventis Menactra Approved; Launch Awaits ACIP Recommendations
Sanofi-Aventis' launch of its meningococcal conjugate vaccine Menactra will await formal recommendations for use by the Centers for Disease Control & Prevention's Advisory Committee on Immunization Practices next month
Vaccine Stockpiling Will Not Encourage Development, Wyeth Exec Says
Vaccine manufacturers look for market growth potential when selecting projects, Wyeth Exec VP George Siber, MD, said